2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Vaccines, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, MPN, CML, Study Population, Human, Adult, Animal Model
PAPER

3725 Navtemadlin synergizes with ruxolitinib to deplete myelofibrosis stem/progenitor cells by upregulating p53 activity and overcoming BCL-2 family-mediated survival signaling

Xiaoli Wang, MD, PhD, Cing-siang Hu2, Cecile Krejsa, PhD3, John O. Mascarenhas, MD4, Ronald Hoffman, MD5
1 Icahn School of Medicine at Mount Sinai, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, United States
3 Kartos Therapeutics, Redwood City, United States
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 Icahn School of Medicine at Mount Sinai, New York, United States

Background:

TP53 wild-type (TP53WT) myelofibrosis (MF) accounts for >90% of cases and is characterized by over expression of the MDM2 protein, a key negative regulator of TP53, in hematopoietic stem/progenitor cells (HSC/HPC; Lu et al., Leukemia 2012). Treatment with navtemadlin (nvtm), a potent, oral MDM2 inhibitor that activates p53, showed disease-modifying activity in relapsed/refractory MF (Mascarenhas et al., Blood 2024). The phase 3 POIESIS study is evaluating nvtm+ruxolitinib (rux) in MF patients (pt) with a suboptimal response to rux (Vachhani et al., Future Oncol 2026). We used low dose nvtm, added onto rux, to investigate effects of this drug combination on primary HSCs/HPCs from MF pts, and to explore the underlying molecular consequences.

Methods:

CD34+ cells from TP53WT MF pt spleens (n=7), peripheral blood (PB, n=3), and from PB of an MF pt with single-hit mutation TP53A273H (c.818G>A) were treated for 24-72 h with vehicle (veh), nvtm, or rux, alone or combined. Low dose nvtm (400 nM) exerted only partial effects, preserving sufficient viability to test combination nvtm+rux effects on CD34+CD38− HSC and CD34+ HPC, as quantified by flow cytometry. Apoptosis (cleaved PARP+), intracellular p53, p21, BCL-2 family members, and cell cycle status were analyzed. Colony-forming assays evaluated nvtm+rux effects on malignant (JAK2V617F) vs normal (JAK2WT) progenitors. Inflammatory cytokines in splenic mononuclear cell culture supernatants were measured at 48 h.

Results:

Nvtm or rux treatment alone significantly reduced TP53WT HSC and HPC numbers compared with veh (all p<0.002). Combination treatment produced significantly greater depletion than either agent alone (all p<0.02). Nvtm+250 nM rux (representing Cmax) was more effective than nvtm+100 nM rux (HPC, p=0.003; HSC, p=0.03). Bliss independence analysis demonstrated synergy in 6 of 8 evaluable TP53WT MF samples.

Combination treatment further reduced the growth of assayable hematopoietic colonies (CFU-GM, BFU-E, CFU-GEMM) compared with single agents (n=5; p=0.03 vs nvtm alone; p=0.08 vs rux alone). Genotyping individual CFU-GM from JAK2V617F pts demonstrated depletion of mutant HPC, with relative sparing of normal HPC. In two MF pts, JAK2WT colonies were absent after treatment with veh, nvtm, or rux but emerged after nvtm+rux (6.5% and 12.1%). Another pt showed an increase in JAK2WT colonies after combination treatment (~6% with veh, nvtm, or rux vs 23.5% with nvtm+rux).

Nvtm+rux induced significantly more apoptosis of MF HPC and HSC at 24 h compared with either agent alone (all p=0.02); this effect persisted through 72 h. Although cell-cycle arrest was not observed with either single agent or their combinations, nvtm+rux significantly reduced the proportion of proliferating (G2/S/M) HPC and HSC (all p<0.05). Synergistic depletion of phenotypically defined HSC/HPC, increased apoptosis, reduced colony formation, and JAK2WT colony enrichment were also observed following treatment of TP53A273H CD34+ cells with nvtm+rux.

Mechanistically, low dose nvtm did not substantially alter expression of anti-apoptotic MCL-1 and BCL-xL, whereas rux reduced the levels of both proteins. Combined nvtm+rux significantly suppressed MCL-1 and BCL-xL expression compared with veh or nvtm alone (all p<0.05). Low dose nvtm increased pro-apoptotic Bax (p=0.03); similar elevations occurred with nvtm+rux. Nvtm-mediated p21 induction, a checkpoint that limits apoptosis, was attenuated with nvtm+rux, potentially preventing escape of MF clones via cell-cycle arrest. Nvtm+rux also reduced the secretion of inflammatory cytokines, including IL-1β and TNF-α, to a greater extent than either single agent.

Conclusions:

Using a sub-therapeutic nvtm dose compared with previous studies at therapeutic concentrations (Clevenger et al., HemaSphere 2023), this investigation demonstrated synergistic activity of add-on nvtm+rux in depleting MF HSCs/HPCs. Even at low nvtm concentrations, combined treatment suppressed survival proteins MCL-1 and BCL-xL, attenuated p21 induction, and maintained p53-mediated up-regulation of Bax, enhancing commitment to apoptosis without inducing cell-cycle arrest. Further, nvtm+rux also suppressed inflammatory cytokine production. Importantly, nvtm+rux preferentially targeted malignant JAK2V617F progenitors. These findings provide strong orthogonal rationale for combining MDM2 and JAK2 inhibitors as a disease-modifying strategy for TP53WT and potentially TP53 single-hit mutant MF.

Xiaoli Wang, MD, PhD: No relevant conflicts of interest to declare.